Skip to main content

Viatris Inc Emerging Markets Segment revenue

  • VTRS · Nasdaq
  • Pharmaceuticals
  • S&P 500
$20.82+0.73%Close 13 Nov 2026

Emerging Markets Segment revenue at Viatris Inc came to $531.1M for the quarter to 30 Sep 2026, down 7.1% from a year earlier.

As Viatris Inc reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 5 Nov 2026.

By quarter

$619.1MDec 2023$628.8MMar 2024$582.3MJun 2024$535.3MSep 2024$514.0MDec 2024$523.1MMar 2025$556.9MJun 2025$571.8MSep 2025$565.8MDec 2025$537.4MMar 2026$543.8MJun 2026$531.1MSep 2026
Viatris Inc Emerging Markets Segment revenue, every reported period
Period endingEmerging Markets Segment revenueChange on a yearFiled
30 Sep 2026$531.1Mdown 7.1%5 Nov 2026
30 Jun 2026$543.8Mdown 2.4%6 Aug 2026
31 Mar 2026$537.4Mup 2.7%7 May 2026
31 Dec 2025$565.8Mup 10.1%26 Feb 2026
30 Sep 2025$571.8Mup 6.8%6 Nov 2025
30 Jun 2025$556.9Mdown 4.4%7 Aug 2025
31 Mar 2025$523.1Mdown 16.8%8 May 2025
31 Dec 2024$514.0Mdown 17.0%27 Feb 2025
30 Sep 2024$535.3Mdown 16.7%7 Nov 2024
30 Jun 2024$582.3Mdown 10.2%8 Aug 2024
31 Mar 2024$628.8Mdown 2.0%9 May 2024
31 Dec 2023$619.1Mup 6.6%28 Feb 2024
30 Sep 2023$642.5Mdown 5.4%8 Nov 2023
30 Jun 2023$648.1Mdown 0.4%7 Aug 2023
31 Mar 2023$641.9Mdown 9.0%8 May 2023
31 Dec 2022$580.6Mdown 20.2%27 Feb 2023
30 Sep 2022$678.9Mdown 14.3%7 Nov 2022
30 Jun 2022$650.9Mdown 25.2%8 Aug 2022
31 Mar 2022$705.2Mdown 6.6%9 May 2022
31 Dec 2021$727.5Mup 15.7%28 Feb 2022
30 Sep 2021$792.5Mup 68.3%8 Nov 2021
30 Jun 2021$870.0Mup 112.0%9 Aug 2021
31 Mar 2021$754.7Mup 119.7%10 May 2021
31 Dec 2020$629.0M—1 Mar 2021
30 Sep 2020$471.0M—10 Nov 2020
30 Jun 2020$410.3M—12 Aug 2020
31 Mar 2020$343.5M—12 May 2020

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Viatris Inc: Brands revenue · Generics revenue · Lipitor revenue · Norvasc revenue · EpiPen® Auto-Injectors revenue · Lyrica ® revenue · Creon ® revenue · Viagra ® revenue · Influvac ® revenue · Zoloft ® revenue · Yupelri ® revenue · Celebrex ® revenue · Effexor ® revenue · Xalabrands revenue · Xanax ® revenue · Amitiza ® revenue · Dymista ® revenue · Developed Markets Segment revenue · Greater China revenue · Japan, Australia and New Zealand Segment revenue · financial statements

Every KPI and segment of VTRS, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.